Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · FILANA THERAPEUTICS, INC. (FLNA)

Filana Therapeutics Q3 net loss $10.7 million, flat; FDA hold on simufilam lifted

Neutral Impact 3 of 5 earnings Written later

Filana Therapeutics reported third-quarter 2026 results with a net loss of $10.7 million, or $0.22 per share, nearly unchanged from $10.8 million a year earlier. The company said the FDA lifted the clinical hold on its simufilam study in September 2026 and expects patient screening to begin by the first quarter of 2027, with year-end 2026 cash guided to $38 million to $42 million.

Key points

  • Q3 2026 net loss was $10.7 million, or $0.22 per share, versus $10.8 million, or $0.22 per share, in Q3 2025.
  • Cash and cash equivalents were $47.0 million at September 30, 2026, and the company has no debt.
  • A $31.25 million litigation settlement escrow payment was made on July 23, 2026, recorded as restricted cash.
  • Net cash used in operations for second-half 2026 is expected to be $11 million to $15 million.

The filing

CompanyFILANA THERAPEUTICS, INC. (FLNA)
Form8-K, current report
Filed with the SECNov 5, 2026, 8:10 AM ET
Accession number0001171843-26-007150

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.